Selenium and the risk of cancer in BRCA1 carriers

Lubinski J,Jaworska K,Durda K,Jakubowska A

The A148T variant of CDKN2A gene in bladder cancer

Borkowska E,Jedrzejczyk A,Kruk A,Traczyk M

New diagnostic test for high risk of breast cancer in Poland

Gorski B

Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients

Byrski T,Gronwald J,Huzarski T,Dent RA

Progress in clinical genetics of prostate cancer

Cybulski C,Woko？orczyk D

BRCA1 mutations in women with familial or early-onset breast cancer and BRCA2 mutations in familial cancer in Estonia

Kristiina Tamboom, Krista Kaasik, Jelena Ar？avskaja, Mare Tekkel, Aili Lilleorg, Peeter Padrik, Andres Metspalu, Toomas Veidebaum

Cancer and Lhermitte-Duclos disease are common in Cowden syndrome patients

Douglas L Riegert-Johnson, Ferga C Gleeson, Maegan Roberts, Krysta Tholen, Lauren Youngborg, Melvin Bullock, Lisa A Boardman

The revised Bethesda guidelines: extent of utilization in a university hospital medical center with a cancer genetics program

Aparna Mukherjee, Thomas J McGarrity, Francesca Ruggiero, Walter Koltun, Kevin McKenna, Lisa Poritz, Maria J Baker

Population screening for hereditary and familial cancer syndromes in Valka district of Latvia

Andrejs Vanags, Ilze ？trumfa, Andris Gardovskis, Viktors Boro？enko, Arnis āboli？？, Uldis Teibe, Genadijs Trofimovi？s, Edvīns Mikla？evi？s, Jānis Gardovskis

MSH6 and PMS2 mutation positive Australian Lynch syndrome families: novel mutations, cancer risk and age of diagnosis of colorectal cancer

Bente A Talseth-Palmer, Mary McPhillips, Claire Groombridge, Allan Spigelman, Rodney J Scott

Is no news good news? Inconclusive genetic test results in BRCA1 and BRCA2 from patients and professionals' perspectives

Audrey Ardern-Jones, Regina Kenen, Elly Lynch, Rebecca Doherty, Rosalind Eeles

High penetrances of BRCA1 and BRCA2 mutations confirmed in a prospective series

P？l M？ller, Lovise M？hle, Lars F Engebretsen, Trond Ludvigsen, Christoffer Jonsrud, Jaran Apold, Anita Vab？, Neal Clark

Surveillance of FAP: a prospective blinded comparison of capsule endoscopy and other GI imaging to detect small bowel polyps

Paul Tescher, Finlay A Macrae, Tony Speer, Damien Stella, Robert Gibson, Jason A Tye-Din, Geeta Srivatsa, Ian T Jones, Kaye Marion

A novel pathogenic MLH1 missense mutation, c.112A > C, p.Asn38His, in six families with Lynch syndrome

Els van Riel, Margreet GEM Ausems, Frans BL Hogervorst, Irma Kluijt, Marielle E van Gijn, Jeanne van Echtelt, Karen Scheidel-Jacobse, Eric FAM Hennekam, Rein P Stulp, Yvonne J Vos, G Johan A Offerhaus, Fred H Menko, Johan JP Gille

Mutation-negative FAP patients with mRNA defects of APC

Condie Michelle W,Tuohy Therese MF,Shires Patricia,Burt Randall W

Breast cancer therapy for BRCA1 carriers: moving towards platinum standard?

Evgeny N Imyanitov

Survival in Norwegian BRCA1 mutation carriers with breast cancer

Anne Hagen, Steinar Tretli, Lovise M？hle, Jaran Apold, Nina Ved？, P？l M？ller

Standard psychological consultations and follow up for women at increased risk of hereditary breast cancer considering prophylactic mastectomy

Murly BM Tan, Eveline MA Bleiker, Marian BE Menke-Pluymers, Arthur R Van Gool, Silvia van Dooren, Bert N Van Geel, Madeleine MA Tilanus-Linthorst, Karina CM Bartels, Jan GM Klijn, Cecile TM Brekelmans, Caroline Seynaeve

Genetic variants in MUTYH are not associated with endometrial cancer risk

Katie A Ashton, Anthony Proietto, Geoffrey Otton, Ian Symonds, Rodney J Scott

Risk perception after genetic counseling in patients with increased risk of cancer

Johanna Rantala, Ulla Platten, Gunilla Lindgren, Bo Nilsson, Brita Arver, Annika Lindblom, Yvonne Brandberg

Penetrance of colorectal cancer among MLH1/MSH2 carriers participating in the colorectal cancer familial registry in Ontario

Yun-Hee Choi, Michelle Cotterchio, Gail McKeown-Eyssen, Monga Neerav, Bharati Bapat, Kevin Boyd, Steven Gallinger, John McLaughlin, Melyssa Aronson, Laurent Briollais

Factors associated with testicular self-examination among unaffected men from multiple-case testicular cancer families

Susan T Vadaparampil, Richard P Moser, Jennifer Loud, June A Peters, Mark H Greene, Larissa Korde

Unusual presentation of Lynch Syndrome

Veronica PCC Yu, Marco Novelli, Stewart J Payne, Sam Fisher, Rebecca A Barnetson, Ian M Frayling, Ann Barrett, David Goudie, Audrey Ardern-Jones, Ros Eeles, Susan Shanley

Australian clinicians and chemoprevention for women at high familial risk for breast cancer

Louise A Keogh, John L Hopper, Doreen Rosenthal, Kelly-Anne Phillips

Early-onset breast cancer in a Lebanese family with Lynch syndrome due to MSH2 gene mutation

Riad Akoum, Albert Ghaoui, Emile Brihi, Maroun Ghabash, Nicolas Hajjar

High frequency of BRCA1, but not CHEK2 or NBS1 (NBN), founder mutations in Russian ovarian cancer patients

Evgeny N Suspitsin, Nathalia Sherina, Daria N Ponomariova, Anna P Sokolenko, Aglaya G Iyevleva, Tatyana V Gorodnova, Olga A Zaitseva, Olga S Yatsuk, Alexandr V Togo, Nathalia N Tkachenko, Grigory A Shiyanov, Oksana S Lobeiko, Nadezhda Krylova, Dmitry E Matsko, Sergey Maximov, Adel F Urmancheyeva, Nathalia V Porhanova, Evgeny N Imyanitov

Hereditary Cancer in Clinical Practice transfers to BioMed Central

Jan Lubiński, Rolf H Sijmons, Rodney J Scott

Large family with both parents affected by distinct BRCA1 mutations: implications for genetic testing

Anna P Sokolenko, Dmitry A Voskresenskiy, Aglaya G Iyevleva, Elena M Bit-Sava, Nadezhda I Gutkina, Maxim S Anisimenko, Nathalia Yu Sherina, Nathalia V Mitiushkina, Yulia M Ulibina, Olga S Yatsuk, Olga A Zaitseva, Evgeny N Suspitsin, Alexandr V Togo, Valery A Pospelov, Sergey P Kovalenko, Vladimir F Semiglazov, Evgeny N Imyanitov

Cancer risk in MLH1, MSH2 and MSH6 mutation carriers; different risk profiles may influence clinical management

Dewkoemar Ramsoekh, Anja Wagner, Monique E van Leerdam, Dennis Dooijes, Carli MJ Tops, Ewout W Steyerberg, Ernst J Kuipers

Penetrance of HNPCC-related cancers in a retrolective cohort of 12 large Newfoundland families carrying a MSH2 founder mutation: an evaluation using modified segregation models

Karen A Kopciuk, Yun-Hee Choi, Elena Parkhomenko, Patrick Parfrey, John McLaughlin, Jane Green, Laurent Briollais

The contribution of CHEK2 to the TP53-negative Li-Fraumeni phenotype

Marielle WG Ruijs, Annegien Broeks, Fred H Menko, Margreet GEM Ausems, Anja Wagner, Rogier Oldenburg, Hanne Meijers-Heijboer, Laura J van't Veer, Senno Verhoef

Molecular genetics analysis of hereditary breast and ovarian cancer patients in India

Nagasamy Soumittra, Balaiah Meenakumari, Tithi Parija, Veluswami Sridevi, Karunakaran N Nancy, Rajaraman Swaminathan, Kamalalayam R Rajalekshmy, Urmila Majhi, Thangarajan Rajkumar

MSH6 syndrome

Janina Suchy, Jan Lubiński

Lynch syndrome (HNPCC)

Józef K？adny, Jan Lubiński

BRCA1 testing

Bohdan Górski, Jan Lubiński

Hereditary breast and ovarian cancer

Jacek Gronwald, Tomasz Byrski, Tomasz Huzarski, Oleg Oszurek, Anna Janicka, Jolanta Szymańska-Pasternak, Bohdan Górski, Janusz Menkiszak, Izabella Rzepka-Górska, Jan Lubiński

MSH2 and MLH1 testing

Grzegorz Kurzawski, Janina Suchy, Jan Lubiński

DNA testing for variants conferring low or moderate increase in the risk of cancer

Grzegorz Kurzawski, Janina Suchy, Cezary Cybulski, Joanna Matyjasik, Tadeusz D？bniak, Bohdan Górski, Tomasz Huzarski, Anna Janicka, Jolanta Szymańska-Pasternak, Jan Lubiński

Encyclopaedia of tumour-associated familial disorders. Part I: from AIMAH to CHIME syndrome

Rolf H Sijmons

Comment on the article Genetic contribution to all cancers: the first demonstration using the model of breast cancers from Poland stratified by age at diagnosis and tumour pathology by Lubinski et al., Breast Cancer Res Treat 2008 Apr 15

Arvids Irmejs, Edvins Mikla？evics, Ilze ？trumfa, Janis Gardovskis

DNA and RNA analyses in detection of genetic predisposition to cancer

Joanna Matyjasik, Bart？omiej Masoj？, Grzegorz Kurzawski

Thyroid cancer in a patient with a germline MSH2 mutation. Case report and review of the Lynch syndrome expanding tumour spectrum

Rein P Stulp, Johanna C Herkert, Arend Karrenbeld, Bart Mol, Yvonne J Vos, Rolf H Sijmons

Opinion on moderate/low cancer genetic risk markers in medical practice including comment on the article Genetic contribution to all cancers: the first demonstration using the model of breast cancers from Poland stratified by age at diagnosis and tumour pathology by Lubinski et al., Breast Cancer Res Treat 2008 Apr 15

Sandra Costa, Fernando C Schmitt

Principles of genetic predisposition to malignancies

Tadeusz D？bniak, Jan Lubiński

Other short opinions/comments on moderate/low cancer genetic risk markers in medical practice and the article Genetic contribution to all cancers: the first demonstration using the model of breast cancers from Poland stratified by age at diagnosis and tumour pathology by Lubinski et al., Breast Cancer Res Treat 2008 Apr 15

Kristiina Aittom？ki

Opinion on moderate/low cancer genetic risk markers in medical practice

Stefan Aretz, Waltraut Friedl

Clinical and genetic aspects of testicular germ cell tumours

Martijn Holzik, Rolf H Sijmons, Josette EHM Hoekstra-Weebers, Dirk T Sleijfer, Harald J Hoekstra

A population-based audit of ethnicity and breast cancer risk in one general practice catchment area in North London, UK: implications for practice

Michelle Ferris, Douglas F Easton, Rebecca J Doherty, Brian HJ Briggs, Michelle Newman, Ifthikhar M Saraf, Sarah Scambler, Lyndon Wagman, Michael T Wyndham, Ann Ward, Rosalind A Eeles

Dear Readers

Familial Multiple Myeloma: Report on Two Families and Discussion of Screening Options

Erica H Gerkes, Mirjam M de Jong, Rolf H Sijmons, Edo Vellenga